Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Sana Biotechnology, Inc. (NASDAQ: SANA) will present a business overview at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 4:00 p.m. PT. CEO Steve Harr will lead the presentation, highlighting the company's innovative focus on engineered cell therapies. Interested parties can access the live webcast on Sana's Investor Relations webpage, with a replay available for 30 days post-conference. Sana aims to transform how diseases are treated by creating advanced cell-based medicines, operating in multiple locations including Seattle and Cambridge.
CAMBRIDGE, Mass. -- Flagship Pioneering and Tessera Therapeutics announced Dr. Michael Severino has been appointed as the new CEO of Tessera. With over 20 years of experience in biopharmaceuticals, Severino previously served as Vice Chairman and President of AbbVie, overseeing the development of numerous FDA-approved therapies. Tessera, known for its innovative GENE WRITING technology, aims to transform genetic medicine. Severino's appointment follows Geoff von Maltzahn’s transition to Board Chair, marking a strategic leadership shift as the company prepares for the next phase of growth with its GENE WRITING platforms.
Sana Biotechnology (NASDAQ: SANA) announced a lease agreement for a new 80,000 sq. ft. manufacturing facility in Bothell, WA, expected to save over $100M in the next three years. This facility will replace the Fremont, CA location and is designed to support multiple product candidates as they approach late-stage clinical development. The company also strengthened its leadership team with the appointments of Snehal Patel as Head of Manufacturing and Julie Lepin as Head of Regulatory Affairs. The move aims to enhance internal manufacturing capabilities without affecting program timelines.
Flagship Pioneering has introduced ProFound Therapeutics, leveraging its ProFoundry™ Platform to discover tens of thousands of novel human proteins, significantly broadening therapeutic targets. The company, founded in 2020, aims to transform human health through unprecedented insights into protein interactions. A commitment of
Sana Biotechnology (NASDAQ: SANA) announced that Terry Fry, M.D., Senior VP and Head of T Cell Therapeutics, will serve as Executive Director at the University of Colorado Gates Institute. Dr. Fry, a leader in CAR T therapies, will maintain his role at Sana while collaborating with academia. The Gates Institute, a $200 million initiative over five years, aims at translating lab findings into cell and gene therapies. The collaboration is expected to enhance Sana's scientific endeavors, reflecting the company's commitment to innovative treatments in gene and cell therapy.
Sana Biotechnology (NASDAQ: SANA) reported its Q1 2022 results, revealing a cash position of $657.4 million as of March 31, down from $746.9 million at the end of 2021. Notable research and development expenses surged to $72.7 million, influenced by increased personnel and manufacturing costs. The net loss narrowed to $31.4 million, or $0.17 per share, compared to $180.6 million in Q1 2021. The company plans to file INDs for its ex vivo and in vivo CAR T programs this year. Additionally, strong conference presentations are scheduled for 2022, highlighting ongoing advancements.
Cellarity has appointed Dr. Sandra Horning to its Board of Directors. Dr. Horning, former Chief Medical Officer at Roche, has extensive experience in drug development, having led the approval of 15 new medicines. Her role is expected to strengthen Cellarity's mission of transforming drug creation through innovative approaches that address complex diseases. The company's unique methodologies utilize high-resolution data and machine learning to enhance drug discovery. This strategic move is viewed positively for future product development.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 3:20 p.m. PT. The presentation will include a business overview by Steve Harr, President and CEO. Investors can access the live webcast on Sana's Investor Relations page, with a replay available for 30 days post-event. Sana focuses on engineered cells as medicines, aiming to repair genes and replace damaged cells, with operations in multiple U.S. locations.
Sana Biotechnology, Inc. (NASDAQ: SANA) announced the acceptance of five abstracts for presentation at the ASGCT 25th Annual Meeting in Washington, D.C. from May 16-19, 2022. The abstracts include two oral presentations on their hypoimmune platform, which aims to enable allogeneic cell transplants without the need for immunosuppression, and two poster presentations on their fusogen platform for targeted gene delivery. The company plans to file two Investigational New Drug applications within the year, focusing on translating their scientific advancements into viable therapeutics.
Tessera Therapeutics has secured over $300 million in Series C financing to advance its GENE WRITING technology aimed at curing genetic diseases. Investors include the Abu Dhabi Investment Authority and Alaska Permanent Fund Corporation. CEO Geoffrey von Maltzahn emphasizes the transformative potential of genetic medicine. The GENE WRITING platform enables precise modifications to DNA, unlocking new treatment possibilities for various conditions. Tessera's innovative approach positions it to potentially lead a new category in genetic medicine.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
